secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0001213900-22-009585
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics appoints Ronald Martell as CEO effective March 15, 2022
---------------------------------------------------------------------------

- Ronald Martell appointed President and CEO, effective March 15, 2022; William Lis transitions to non-executive Chairperson.
- Martell receives $675,000 annual salary, 50% bonus target, and option to purchase 4.5% of outstanding shares vesting over 4 years.
- Additional 'True-Up Option' for 1.0% of shares granted if Jasper closes equity financing ≥$50 million after start date.
- Martell brings 30+ years biotech experience including CEO roles at MorphImmune, Nuvelution, and Achieve Life Sciences.
- If terminated without cause or for good reason, Martell receives 18 months base salary subject to release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390022009585/0001213900-22-009585-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390022009585/ea156240-8k_jasperther.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-009585

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer